CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research methodology
1.4.1. Primary research
1.4.2. Secondary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO Perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top impacting factors
3.2.2. Top investment pockets
3.3. Porter’s five forces analysis
3.3.1. Moderate bargaining power of suppliers
3.3.2. Low threat of new entrants
3.3.3. Low threat of substitutes
3.3.4. Low intensity of rivalry
3.3.5. Low bargaining power of buyers
3.4. Market dynamics
3.4.1. Drivers
3.4.1.1. Rise in incidences of bacterial infections
3.4.1.2. Availability of generic medications
3.4.1.3. Significant demand for macrolides from emerging countries
3.4.2. Restraints
3.4.2.1. Rise in antimicrobial resistance
3.4.2.2. Side effects associated with macrolide antibiotics
3.4.3. Opportunities
3.4.3.1. Rise in investments in research and development activities
CHAPTER 4: MACROLIDE ANTIBIOTICS MARKET, BY DRUG TYPE
4.1. Overview
4.1.1. Market size and forecast
4.2. Azithromycin
4.2.1. Key market trends, growth factors and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market share analysis by country
4.3. Erythromycin
4.3.1. Key market trends, growth factors and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market share analysis by country
4.4. Others
4.4.1. Key market trends, growth factors and opportunities
4.4.2. Market size and forecast, by region
4.4.3. Market share analysis by country
CHAPTER 5: MACROLIDE ANTIBIOTICS MARKET, BY ROUTE OF ADMINISTRATION
5.1. Overview
5.1.1. Market size and forecast
5.2. Oral
5.2.1. Key market trends, growth factors and opportunities
5.2.2. Market size and forecast, by region
5.2.3. Market share analysis by country
5.3. Parenteral
5.3.1. Key market trends, growth factors and opportunities
5.3.2. Market size and forecast, by region
5.3.3. Market share analysis by country
5.4. Others
5.4.1. Key market trends, growth factors and opportunities
5.4.2. Market size and forecast, by region
5.4.3. Market share analysis by country
CHAPTER 6: MACROLIDE ANTIBIOTICS MARKET, BY INDICATION
6.1. Overview
6.1.1. Market size and forecast
6.2. Respiratory Tract Infections
6.2.1. Key market trends, growth factors and opportunities
6.2.2. Market size and forecast, by region
6.2.3. Market share analysis by country
6.3. Skin Infections
6.3.1. Key market trends, growth factors and opportunities
6.3.2. Market size and forecast, by region
6.3.3. Market share analysis by country
6.4. Sexually Transmitted Infections
6.4.1. Key market trends, growth factors and opportunities
6.4.2. Market size and forecast, by region
6.4.3. Market share analysis by country
6.5. Gastrointestinal Infections
6.5.1. Key market trends, growth factors and opportunities
6.5.2. Market size and forecast, by region
6.5.3. Market share analysis by country
6.6. Others
6.6.1. Key market trends, growth factors and opportunities
6.6.2. Market size and forecast, by region
6.6.3. Market share analysis by country
CHAPTER 7: MACROLIDE ANTIBIOTICS MARKET, BY DISTRIBUTION CHANNEL
7.1. Overview
7.1.1. Market size and forecast
7.2. Hospital Pharmacies
7.2.1. Key market trends, growth factors and opportunities
7.2.2. Market size and forecast, by region
7.2.3. Market share analysis by country
7.3. Drug Stores and Retail Pharmacies
7.3.1. Key market trends, growth factors and opportunities
7.3.2. Market size and forecast, by region
7.3.3. Market share analysis by country
7.4. Online Providers
7.4.1. Key market trends, growth factors and opportunities
7.4.2. Market size and forecast, by region
7.4.3. Market share analysis by country
CHAPTER 8: MACROLIDE ANTIBIOTICS MARKET, BY REGION
8.1. Overview
8.1.1. Market size and forecast By Region
8.2. North America
8.2.1. Key market trends, growth factors and opportunities
8.2.2. Market size and forecast, by Drug Type
8.2.3. Market size and forecast, by Route of Administration
8.2.4. Market size and forecast, by Indication
8.2.5. Market size and forecast, by Distribution Channel
8.2.6. Market size and forecast, by country
8.2.6.1. U.S.
8.2.6.1.1. Market size and forecast, by Drug Type
8.2.6.1.2. Market size and forecast, by Route of Administration
8.2.6.1.3. Market size and forecast, by Indication
8.2.6.1.4. Market size and forecast, by Distribution Channel
8.2.6.2. Canada
8.2.6.2.1. Market size and forecast, by Drug Type
8.2.6.2.2. Market size and forecast, by Route of Administration
8.2.6.2.3. Market size and forecast, by Indication
8.2.6.2.4. Market size and forecast, by Distribution Channel
8.2.6.3. Mexico
8.2.6.3.1. Market size and forecast, by Drug Type
8.2.6.3.2. Market size and forecast, by Route of Administration
8.2.6.3.3. Market size and forecast, by Indication
8.2.6.3.4. Market size and forecast, by Distribution Channel
8.3. Europe
8.3.1. Key market trends, growth factors and opportunities
8.3.2. Market size and forecast, by Drug Type
8.3.3. Market size and forecast, by Route of Administration
8.3.4. Market size and forecast, by Indication
8.3.5. Market size and forecast, by Distribution Channel
8.3.6. Market size and forecast, by country
8.3.6.1. Germany
8.3.6.1.1. Market size and forecast, by Drug Type
8.3.6.1.2. Market size and forecast, by Route of Administration
8.3.6.1.3. Market size and forecast, by Indication
8.3.6.1.4. Market size and forecast, by Distribution Channel
8.3.6.2. France
8.3.6.2.1. Market size and forecast, by Drug Type
8.3.6.2.2. Market size and forecast, by Route of Administration
8.3.6.2.3. Market size and forecast, by Indication
8.3.6.2.4. Market size and forecast, by Distribution Channel
8.3.6.3. UK
8.3.6.3.1. Market size and forecast, by Drug Type
8.3.6.3.2. Market size and forecast, by Route of Administration
8.3.6.3.3. Market size and forecast, by Indication
8.3.6.3.4. Market size and forecast, by Distribution Channel
8.3.6.4. Italy
8.3.6.4.1. Market size and forecast, by Drug Type
8.3.6.4.2. Market size and forecast, by Route of Administration
8.3.6.4.3. Market size and forecast, by Indication
8.3.6.4.4. Market size and forecast, by Distribution Channel
8.3.6.5. Spain
8.3.6.5.1. Market size and forecast, by Drug Type
8.3.6.5.2. Market size and forecast, by Route of Administration
8.3.6.5.3. Market size and forecast, by Indication
8.3.6.5.4. Market size and forecast, by Distribution Channel
8.3.6.6. Rest of Europe
8.3.6.6.1. Market size and forecast, by Drug Type
8.3.6.6.2. Market size and forecast, by Route of Administration
8.3.6.6.3. Market size and forecast, by Indication
8.3.6.6.4. Market size and forecast, by Distribution Channel
8.4. Asia-Pacific
8.4.1. Key market trends, growth factors and opportunities
8.4.2. Market size and forecast, by Drug Type
8.4.3. Market size and forecast, by Route of Administration
8.4.4. Market size and forecast, by Indication
8.4.5. Market size and forecast, by Distribution Channel
8.4.6. Market size and forecast, by country
8.4.6.1. Japan
8.4.6.1.1. Market size and forecast, by Drug Type
8.4.6.1.2. Market size and forecast, by Route of Administration
8.4.6.1.3. Market size and forecast, by Indication
8.4.6.1.4. Market size and forecast, by Distribution Channel
8.4.6.2. China
8.4.6.2.1. Market size and forecast, by Drug Type
8.4.6.2.2. Market size and forecast, by Route of Administration
8.4.6.2.3. Market size and forecast, by Indication
8.4.6.2.4. Market size and forecast, by Distribution Channel
8.4.6.3. India
8.4.6.3.1. Market size and forecast, by Drug Type
8.4.6.3.2. Market size and forecast, by Route of Administration
8.4.6.3.3. Market size and forecast, by Indication
8.4.6.3.4. Market size and forecast, by Distribution Channel
8.4.6.4. Australia
8.4.6.4.1. Market size and forecast, by Drug Type
8.4.6.4.2. Market size and forecast, by Route of Administration
8.4.6.4.3. Market size and forecast, by Indication
8.4.6.4.4. Market size and forecast, by Distribution Channel
8.4.6.5. South Korea
8.4.6.5.1. Market size and forecast, by Drug Type
8.4.6.5.2. Market size and forecast, by Route of Administration
8.4.6.5.3. Market size and forecast, by Indication
8.4.6.5.4. Market size and forecast, by Distribution Channel
8.4.6.6. Rest of Asia-Pacific
8.4.6.6.1. Market size and forecast, by Drug Type
8.4.6.6.2. Market size and forecast, by Route of Administration
8.4.6.6.3. Market size and forecast, by Indication
8.4.6.6.4. Market size and forecast, by Distribution Channel
8.5. LAMEA
8.5.1. Key market trends, growth factors and opportunities
8.5.2. Market size and forecast, by Drug Type
8.5.3. Market size and forecast, by Route of Administration
8.5.4. Market size and forecast, by Indication
8.5.5. Market size and forecast, by Distribution Channel
8.5.6. Market size and forecast, by country
8.5.6.1. Brazil
8.5.6.1.1. Market size and forecast, by Drug Type
8.5.6.1.2. Market size and forecast, by Route of Administration
8.5.6.1.3. Market size and forecast, by Indication
8.5.6.1.4. Market size and forecast, by Distribution Channel
8.5.6.2. Saudi Arabia
8.5.6.2.1. Market size and forecast, by Drug Type
8.5.6.2.2. Market size and forecast, by Route of Administration
8.5.6.2.3. Market size and forecast, by Indication
8.5.6.2.4. Market size and forecast, by Distribution Channel
8.5.6.3. South Africa
8.5.6.3.1. Market size and forecast, by Drug Type
8.5.6.3.2. Market size and forecast, by Route of Administration
8.5.6.3.3. Market size and forecast, by Indication
8.5.6.3.4. Market size and forecast, by Distribution Channel
8.5.6.4. Rest of LAMEA
8.5.6.4.1. Market size and forecast, by Drug Type
8.5.6.4.2. Market size and forecast, by Route of Administration
8.5.6.4.3. Market size and forecast, by Indication
8.5.6.4.4. Market size and forecast, by Distribution Channel
CHAPTER 9: COMPETITIVE LANDSCAPE
9.1. Introduction
9.2. Top winning strategies
9.3. Product mapping of top 10 player
9.4. Competitive dashboard
9.5. Competitive heatmap
9.6. Top player positioning, 2022
CHAPTER 10: COMPANY PROFILES
10.1. Abbott Laboratories
10.1.1. Company overview
10.1.2. Key executives
10.1.3. Company snapshot
10.1.4. Operating business segments
10.1.5. Product portfolio
10.1.6. Business performance
10.2. Pfizer Inc.
10.2.1. Company overview
10.2.2. Key executives
10.2.3. Company snapshot
10.2.4. Operating business segments
10.2.5. Product portfolio
10.2.6. Business performance
10.3. Alkem Laboratories Ltd.
10.3.1. Company overview
10.3.2. Key executives
10.3.3. Company snapshot
10.3.4. Operating business segments
10.3.5. Product portfolio
10.3.6. Business performance
10.4. Sun Pharmaceutical Industries Limited
10.4.1. Company overview
10.4.2. Key executives
10.4.3. Company snapshot
10.4.4. Operating business segments
10.4.5. Product portfolio
10.4.6. Business performance
10.5. Teva Pharmaceutical Industries Limited
10.5.1. Company overview
10.5.2. Key executives
10.5.3. Company snapshot
10.5.4. Operating business segments
10.5.5. Product portfolio
10.5.6. Business performance
10.5.7. Key strategic moves and developments
10.6. Wellona Pharma Private Limited.
10.6.1. Company overview
10.6.2. Key executives
10.6.3. Company snapshot
10.6.4. Operating business segments
10.6.5. Product portfolio
10.7. Bristol Laboratories Ltd.
10.7.1. Company overview
10.7.2. Key executives
10.7.3. Company snapshot
10.7.4. Operating business segments
10.7.5. Product portfolio
10.8. Crescent Pharma Limited
10.8.1. Company overview
10.8.2. Key executives
10.8.3. Company snapshot
10.8.4. Operating business segments
10.8.5. Product portfolio
10.9. Merck & Co., Inc.
10.9.1. Company overview
10.9.2. Key executives
10.9.3. Company snapshot
10.9.4. Operating business segments
10.9.5. Product portfolio
10.9.6. Business performance
10.9.7. Key strategic moves and developments
10.10. Zydus Lifesciences Limited
10.10.1. Company overview
10.10.2. Key executives
10.10.3. Company snapshot
10.10.4. Operating business segments
10.10.5. Product portfolio
10.10.6. Business performance
10.10.7. Key strategic moves and developments
*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/
